Funding for this research was provided by:
Lind Pharma, Inc.
Received: 23 August 2021
Accepted: 20 December 2021
First Online: 1 February 2022
: All animal experiments were conducted in compliance with institutional regulations, and the study protocols were approved by the Institutional Animal Care and Committee of Niigata University.
: Y. Sakai. is the CEO of Lind Pharma, Inc. Y. Sawa and S. Miyagawa are the scientific advisers of Lind Pharma Inc. The ONO-1301 was provided by Lind Pharma Inc.